Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00262847
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:13.693418+00:00
Published At
2013-09-18T00:00:00+00:00
Record Updated At
2019-07-23
Results Posted At
2013-09-18
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Malignant Ovarian Mixed Epithelial Tumor", "Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Undifferentiated Fallopian Tube Carcinoma", "Undifferentiated Ovarian Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-07-23"
protocolSection.identificationModule.nctId
"NCT00262847"
protocolSection.identificationModule.officialTitle
"A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2013-09-18"

Study condition terms

  • Fallopian Tube Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Malignant Ovarian Mixed Epithelial Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Brenner Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIA Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Undifferentiated Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Undifferentiated Ovarian Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.